NCT04619290 is a Phase 1 clinical trial of Sublingual Methylene blue in Sars Cov 2, sponsored by Hospital Reg. Lic. Adolfo Lopez Mateos.

Who is sponsoring NCT04619290?

NCT04619290 is sponsored by Hospital Reg. Lic. Adolfo Lopez Mateos.

What drugs are being tested in NCT04619290?

Interventions in NCT04619290: Sublingual Methylene blue, Control patients.

What condition does NCT04619290 study?

NCT04619290 studies Sars Cov 2.

Is NCT04619290 still recruiting?

NCT04619290 is currently status unknown. Last updated 12 November 2020.

Last reviewed 2020-11-12 · How we verify

NCT04619290

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Outpatient Treatment With CoVid-19 With Prexablu

Status unknown Phase 1 Last updated 12 November 2020

What this trial tests

Phase 1 trial testing Sublingual Methylene blue in Sars Cov 2 in 46 participants. Status unknown.

Timeline

12 October 2020

Primary endpoint
30 November 2020

30 December 2020

Quick facts

Lead sponsor	Hospital Reg. Lic. Adolfo Lopez Mateos
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	12 October 2020
Primary completion	30 November 2020
Estimated completion	30 December 2020
Sites	1 location across Mexico

Drugs / interventions tested

Sublingual Methylene blue — full drug profile →
Control patients

Conditions studied

Sars Cov 2 — all drugs for Sars Cov 2 →

Sponsor

Hospital Reg. Lic. Adolfo Lopez Mateos

Who can join

18 and older, any sex, with Sars Cov 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Within the epidemic context of phase 3 in Mexico, the implementation of new treatments that have been shown to be beneficial for patients in other countries is an urgent need. Methylene blue (MB, the oxidized form, blue color) has been used in many different clinical medicine areas, ranging from malaria to orthopedics. Methylene blue absorbs energy directly from a light source and then transfers this energy to molecules of oxygen creating singlet oxygen (O2), which is the first electronic excited state of molecular oxygen (O2). Singlet oxygen is extremely electrophilic; thus, it can directly oxidize electron-rich double bonds in biological molecules and macromolecules. For this reason, methylene blue has been used as a photosensitizer in the treatment of cancer and the protection of serum from viral agents. Methylene blue can be reactivated using energy from a light source in the body until processed out through the kidneys.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Hospital Reg. Lic. Adolfo Lopez Mateos trials

Trials by the same sponsor.

NCT04611256 — Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04619290 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Reg. Lic. Adolfo Lopez Mateos
Last refreshed: 12 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04619290.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing